| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10514001 | Journal of Clinical Epidemiology | 2014 | 10 Pages |
Abstract
Pharmacologic SPAF cost-effectiveness models have been extensively reported, but many may have flaws giving reason for decision makers to use caution. We provide 10 recommendations to avoid common flaws in SPAF cost-effectiveness models.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Brendan L. Limone, William L. Baker, Elizabeth S. Mearns, C. Michael White, Jeffrey Kluger, Craig I. Coleman,